China NMPA Accepts Nicox NCX 470 NDA; Decision In 18 Months

With NMPA acceptance confirmed on 10 September 2026, Nicox SA's NCX 470 glaucoma NDA has formally entered China's regulatory review queue, a milestone that sets the clock on a parallel multi-jurisdictional approval strategy spanning the U.S., China, and Japan simultaneously.

The dossier, submitted in August 2026 by Nicox's exclusive Chinese licensee Ocumension Therapeutics (which markets the asset as OT-301), covers NCX 470 as a treatment to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension. China carries no fixed statutory review period, but the NMPA process typically resolves within 12 to 18 months of submission. Nicox has indicated the Chinese decision is expected to follow the U.S. PDUFA date of 30 April 2027, placing the China outcome likely in late 2027 or early 2028.

For regulatory affairs leads tracking multi-regional NDA sequencing, the timeline alignment is notable. Both the Mont Blanc and Denali Phase 3 trials were designed to satisfy regulatory requirements in the U.S. and China concurrently, with Ocumension contributing 50% of Denali trial costs. That shared clinical data package underpins both submissions, reducing the dossier divergence that typically complicates parallel filings under 21 CFR Part 314 and NMPA pathways.

Ocumension holds rights to develop and commercialise NCX 470 across Chinese, Korean, and Southeast Asian markets under a licence arrangement totalling €18 million in fees paid to Nicox. Tiered royalties on Ocumension sales range from 6% to 12%. Ocumension already maintains an ophthalmology sales force across China, a commercial infrastructure factor that bears directly on launch-readiness planning once a regulatory decision is issued.

NCX 470 is a nitric oxide-donating bimatoprost molecule designed to lower IOP via two distinct pathways: prostaglandin analog activity and nitric oxide-mediated enhancement of aqueous humor drainage through soluble guanylate cyclase activation. Japan Phase 3 trials remain ongoing, with results pending as the third leg of Nicox's regional programme.

The April 2027 FDA PDUFA date remains the nearest hard checkpoint against which supply chain, CMC readiness, and commercial planning timelines will be measured.

Source: Nicox SA via GlobeNewswire, 11 September 2026.